No Data
No Data
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and
Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.Shares of Argan, Inc. (NYSE:AGX) rose sharply during Friday's session after the company reported better-than-expected fir
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events.
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May,
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Joseph Pantginis maintains $Esperion Therapeutics(ESPR.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate